Biotechnological Inventions

Directive in the legal protection of biotechnological innovations

Directive 98/44/EC, the alleged ‘Biotech Directive’ on the appropriate security of biotechnological innovations had been adopted in 1998 and implemented by all EU countries.

Professional Group from the development and ramifications of patent law in neuro-scientific biotechnology and hereditary engineering

The Biotech Directive needs regular reporting on certain issues in the area of biotechnology and hereditary engineering. To produce information on present scientific advancements and their implications on patent law, the Commission put up an expert team aided by the mission to deliver expertise, analysis and responses in the rapid evolutions inside biotechnological field.

2nd report from the development and implications of patent legislation in the field of biotechnology and hereditary engineering (2005)

This report addresses advancements and ramifications of patent law in neuro-scientific biotechnology and hereditary engineering. It focuses on dilemmas in your community of patents regarding gene sequences plus the patentability of inventions concerning stem cells. It also states in the utilization of the Directive.

First report from the development and implications of patent legislation in neuro-scientific biotechnology and hereditary manufacturing (2002)

This report required the swift utilization of the 1998 Directive in the appropriate protection of biotechnological innovations to quit Europe dropping behind its rivals in this industry, damaging its total efforts to become more competitive economic climate worldwide. The report in addition addresses key conditions of this Directive, such as the potential patenting of plants and creatures in addition to patenting of elements isolated from human body or otherwise created, including stem cells.